CDK2 and leukemia: In addition, recent studies demonstrated that Roscovitine (a potent small molecule inhibitor of CDK2, and weak inhibitor of CDK1, 5, 7, and 9) treatment inhibits the function of the alloreactive T cells while allowing preservation of leukemia-specific and pathogen-specific effectors (Nellore et al., 2014).